Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2020 · 10-Q
Revenue$252.57M$252.57M+4.5% vs Q2 2019 Net Income$37.49M$37.49M+100.2% vs Q2 2019 EPS Diluted$0.72$0.72+105.7% vs Q2 2019 Gross Profit$127,000,000+13.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$29,901,000−47.9% Free Cash Flowderived$20,428,000+130.3% Margins · derivedGross margin50.3%+4.0 pt vs Q2 2019
Operating margin19.7%+8.9 pt vs Q2 2019
Net margin14.8%+7.1 pt vs Q2 2019
ended Sep 28, 2019 · filed Nov 1, 2019 · 34 d after period end